QC
ARTV

Quadrature Capital’s Artiva Biotherapeutics ARTV Stock Holding History

Quadrature Capital’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$479K Buy
+49,345
New +$449K ﹤0.01% 1019

Other funds holding ARTV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return

Quadrature Capital's ARTV Position: Q2 2026 in Review

Quadrature Capital opened a new position in Artiva Biotherapeutics (ARTV) in Q2 2026: 49,345 shares worth $479K. The stake represents ﹤0.01% of the portfolio and ranks #1019 among its holdings.

12 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Quadrature Capital held 49,345 shares of Artiva Biotherapeutics worth $479K as of Q2 2026.
  • Artiva Biotherapeutics was a new Quadrature Capital position in Q2 2026.
  • Artiva Biotherapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1019 holding.
  • 12 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.